Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
- Written by PR Newswire
 |
- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment
SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered...
